TFG Asset Management GP Ltd Invests $4.85 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

TFG Asset Management GP Ltd bought a new position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 192,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,852,000. Celldex Therapeutics comprises about 1.0% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 19th biggest holding. TFG Asset Management GP Ltd owned 0.29% of Celldex Therapeutics at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Values First Advisors Inc. grew its holdings in shares of Celldex Therapeutics by 20.0% in the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company’s stock worth $733,000 after purchasing an additional 4,837 shares during the last quarter. Barclays PLC lifted its position in Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock worth $4,431,000 after buying an additional 76,207 shares in the last quarter. SG Americas Securities LLC lifted its position in Celldex Therapeutics by 24.4% during the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company’s stock worth $639,000 after buying an additional 4,967 shares in the last quarter. Invesco Ltd. lifted its position in Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company’s stock worth $1,064,000 after buying an additional 871 shares in the last quarter. Finally, Sovran Advisors LLC acquired a new position in Celldex Therapeutics during the 4th quarter worth about $2,867,000.

Celldex Therapeutics Trading Down 0.1%

Celldex Therapeutics stock opened at $20.35 on Friday. The company has a market cap of $1.35 billion, a PE ratio of -7.92 and a beta of 1.39. The company’s 50-day moving average is $18.91 and its two-hundred day moving average is $22.38. Celldex Therapeutics, Inc. has a 1 year low of $14.40 and a 1 year high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. Research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CLDX shares. The Goldman Sachs Group reduced their price target on shares of Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating on the stock in a research report on Friday, May 9th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley reduced their price target on shares of Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. Finally, Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They set a “buy” rating and a $64.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.90.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.